Daniel A Vallera

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Venues

Molecular cancer therapeutics

Cancers

Biomedicines

Journal of clinical medicine

University of Minnesota

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Minnesota Apr 07 1978

United States

Professor :: Radiation Oncology

Publications

Jacob Petersburg, Daniel A Vallera, Carston R Wagner
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings. Molecular cancer therapeutics 22 (3) (2023)
Jacob Petersburg, Daniel A Vallera, Carston R Wagner
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings. Molecular cancer therapeutics 22 (3) (2023)
Jacob Petersburg, Daniel A Vallera, Carston R Wagner
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings. Molecular cancer therapeutics 22 (3) (2023)
Jacob Petersburg, Daniel A Vallera, Carston R Wagner
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings. Molecular cancer therapeutics 22 (3) (2023)
Jacob Petersburg, Daniel A Vallera, Carston R Wagner
Eradication of Heterogeneous Tumors by T-Cells Targeted with Combination Bispecific Chemically Self-Assembled Nanorings (CSANs). Molecular cancer therapeutics (2022)
Daniel A Vallera, Felix Oh, Behiye Kodal, Peter Hinderlie, Melissa A Geller, Jeffrey S Miller, Martin Felices
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. Cancers 13 (16) (2021)
Daniel A Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick, Brianna Ettestad, Caroline Hallstrom, Nicholas A Zorko, Arpit Rao, Naomi Fujioka, Charles J Ryan, Melissa A Geller, Jeffrey S Miller, Martin Felices
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers 12 (9) (2020)
Felix Oh, Jaime F Modiano, Veronika Bachanova, Daniel A Vallera
Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors. Biomolecules 10 (6) (2020)
Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F Kaminski, Sarah Cooley, Daniel J Weisdorf, Daniel A Vallera, Jeffrey S Miller, Veronika Bachanova
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood advances 3 (6) (2020)
Cathrine Elisabeth Olsen, Lawrence H Cheung, Anette Weyergang, Kristian Berg, Daniel A Vallera, Michael G Rosenblum, Pål Kristian Selbo
Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization. Journal of clinical medicine 9 (1) (2019)
Daniel A Vallera, Robert J Kreitman
Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity. Biomedicines 7 (1) (2018)

Daniel A Vallera.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel A Vallera